Published on
Last updated on
Cisema experts cited in drug-device combination news
Cisema's regulatory affairs consultant Anna King was recently cited by Bioworld in their article titled "China clarifies rules for registration and classification of drug-device combinations".
Mrs King and Stephen Sunderland from LEK Consulting LLC gave their views on the recent clarification from NMPA regarding drug-device combination products.
“Before the new regulation, a manufacturer had to try their luck and decide themselves whether they should submit their application to the technical review body for drugs CDE or the technical review body for medical device CMDE,” said King.
“With the new regulation, the procedure and responsibility are very clear now,” she said.
We have published more about the recent NMPA announcement in our blog post "New Preconditions for Marketing Approvals of Combination Products in China".
Contact Cisema if you would like to learn more.
Related News
Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices
Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements
Vietnam Authorities Step Up Cosmetic Recalls as Enforcement Tightens
Vietnam’s Drug Administration (DAV) is stepping up cosmetic product recalls as post-market surveillance tightens.
BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation
BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.